Skip to content

Ionis Pharmaceuticals IONS Changes in unrecognized tax benefits

Changes in unrecognized tax benefits at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$1.61M-166%

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxContingencies.

The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's changes in unrecognized tax benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's changes in unrecognized tax benefits?
Ionis Pharmaceuticals (IONS) reported changes in unrecognized tax benefits of $3.04M in Q4 2025.
What does changes in unrecognized tax benefits mean?
The financial impact of reserves for uncertain tax positions.
How do you interpret changes in unrecognized tax benefits?
Increases suggest higher uncertainty or potential future tax liabilities from audits.
How does changes in unrecognized tax benefits compare across companies?
Standard disclosure required under accounting standards for tax contingencies.